Medicines that inhibit COX can alleviate inflammation and pain symptoms. Medications that inhibit Cyclooxygenase activity, such as aspirin, have been available to the public for around 100 years.

Recently, KangaBio announced that its independently developed "Tumor-Specific Recombinant IL-12 Fc Fusion Protein for Injection" (pipeline code: KGX101) clinical trial application (IND) has been officially approved by the U.S. FDA.

This article summarized the latest R&D progress of Diroximel fumarate, the Mechanism of Action for Diroximel fumarate, and the drug target R&D trends for Diroximel fumarate.

Recently, Johnson & Johnson announced the results of its Phase 3 clinical trial for its anti-IL-23 antibody Tremfya (guselkumab) in treating moderate to severe ulcerative colitis (UC).

PD-1, or programmed cell death protein 1, is a crucial immune checkpoint receptor found on the surface of certain immune cells in the human body.

Recently, AbbVie announced that the National Medical Products Administration (NMPA) of China has approved two new indications for its JAK inhibitor, upadacitinib extended-release tablets.

This article summarized the latest R&D progress of Doxofylline, the Mechanism of Action for Doxofylline, and the drug target R&D trends for Doxofylline.

The US FDA has approved Biosyngen's BST02 for clinical trials. This cutting-edge TIL liver cancer therapy is a pioneer in cellular and gene therapy and is the first universal liver cancer TIL treatment to progress to the clinical stage.

This article summarized the latest R&D progress of Doravirine, the Mechanism of Action for Doravirine, and the drug target R&D trends for Doravirine.

The surface of the influenza virus is distributed with three important proteins, namely, hemagglutinin (HA), neuraminidase (NA), and matrix protein (M2), each playing an important role in the transmission cycle of the influenza virus.

Genentech has communicated that the FDA has given approval for Vabysmo®(faricimab-svoa) to be used in treating macular edema that occurs after retinal vein occlusion.

This article summarized the latest R&D progress of Cefazolin Sodium, the mechanism of action for Cefazolin Sodium, and the drug target R&D trends for Cefazolin Sodium.